Literature DB >> 11877294

Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6.

Hideaki Ishikawa1, Naohiro Tsuyama, Saeid Abroun, Shangqin Liu, Fu-Jun Li, Osamu Taniguchi, Michio M Kawano.   

Abstract

Specific intracellular signals mediated by interleukin-6 (IL-6) receptor complexes, such as signal transducer and activator of transcription 3 (STAT 3) and extracellular signal-regulated kinase (ERK) 1/2, are considered to be responsible for inducing a variety of cellular responses. In multiple myeloma, IL-6 only enhanced the proliferation of CD45+ tumor cells that harbored the IL-6-independent activation of src family kinases even though STAT3 and ERK1/2 could be activated in response to IL-6 in both CD45+ and CD45(minus sign) cells. Furthermore, the IL-6-induced proliferation of CD45+ U266 myeloma cells was significantly suppressed by Lyn-specific antisense oligodeoxynucleotides or a selective src kinase inhibitor. These results indicate that the activation of both STAT3 and ERK1/2 is not enough for IL-6-induced proliferation of myeloma cell lines that require src family kinase activation independent of IL-6 stimulation. Thus, the activation of the src family kinases associated with CD45 expression is a prerequisite for the proliferation of myeloma cell lines by IL-6. We propose a mechanism for IL-6-induced cell proliferation that is strictly dependent upon the cellular context in myelomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877294     DOI: 10.1182/blood.v99.6.2172

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries.

Authors:  Ronald L Johnson; Ruili Huang; Ajit Jadhav; Noel Southall; Jennifer Wichterman; Ryan MacArthur; Menghang Xia; Kun Bi; John Printen; Christopher P Austin; James Inglese
Journal:  Mol Biosyst       Date:  2009-06-19

2.  Logic programming reveals alteration of key transcription factors in multiple myeloma.

Authors:  Bertrand Miannay; Stéphane Minvielle; Olivier Roux; Pierre Drouin; Hervé Avet-Loiseau; Catherine Guérin-Charbonnel; Wilfried Gouraud; Michel Attal; Thierry Facon; Nikhil C Munshi; Philippe Moreau; Loïc Campion; Florence Magrangeas; Carito Guziolowski
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

3.  Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.

Authors:  Om Prakash; O Rama Swamy; Xiochang Peng; Zhen-Ya Tang; Li Li; Janet E Larson; J Craig Cohen; Javed Gill; Gist Farr; Suizhao Wang; Felipe Samaniego
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

4.  Growth mechanism of human myeloma cells by interleukin-6.

Authors:  Michio M Kawano; Hideaki Ishikawa; Naohiro Tsuyama; Saeid Abroun; Shangqin Liu; Fu-Jun Li; Ken-ichiro Otsuyama; Xu Zheng
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Feda Azab; Barbara Muz; Micah Luderer; Jack Arbiser; Abdel Kareem Azab
Journal:  Leuk Lymphoma       Date:  2015-11-16

6.  Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Authors:  Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Daisuke Kurita; Hitomi Sakagami; Hiromichi Takahashi; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

Review 7.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

8.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 9.  Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.

Authors:  Hideaki Ishikawa; Naohiro Tsuyama; Michio M Kawano
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

Review 10.  Apoptotic signaling in multiple myeloma: therapeutic implications.

Authors:  Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.